Avantor (AVTR) free cash flow

Free cash flow · fiscal 2025
$495.00M

Avantor (AVTR) generated free cash flow of $495.00M in fiscal 2025 (the year ended December 31, 2025). That is 28.5% lower than the $692.00M of fiscal 2024. Figures as of 18 Nov 2026, 12:17 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$495.00M
Change on fiscal 2024
−28.5%
Growth, 5 years
−10.6% a year
Highest on record
$868.20Mfiscal 2020
Lowest on record
-$192.70Mfiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Avantor free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow shrank at a compound 10.6% a year. Across the 9 fiscal years on record (2017–2025), the highest was $868.20M in fiscal 2020 and the lowest -$192.70M in fiscal 2017.

History · 9 fiscal years

Free cash flow by fiscal year

Avantor free cash flow, year by year

Avantor (AVTR) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$495.00M 28.5% down
2024$692.00M 4.4% down
2023$723.60M 1.9% up
2022$710.20M 15.7% down
2021$842.50M 3.0% down
2020$868.20M 187.1% up
2019$302.40M 85.7% up
2018$162.80M—
2017-$192.70M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Avantor and comparable companies
CompanyFree cash flowFiscal year
BioMarin Pharmaceutical BMRN$717.02M2025
Avantor AVTR$495.00M2025
Ensign Group ENSG$370.71M2025
Vaxcyte PCVX-$712.55M2025
Bio-Rad Laboratories BIO$374.60M2025
Molina Healthcare MOH-$636.00M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AVTR

Avantor, figure by figure

Avantor (AVTR) overview: price, valuation and scorecardAll health care companies by market value

Avantor free cash flow: questions and answers

What is Avantor's free cash flow?

Avantor (AVTR) generated free cash flow of $495.00M in fiscal 2025 (the year ended December 31, 2025). That is 28.5% lower than the $692.00M of fiscal 2024.

What is the growth rate of Avantor's free cash flow?

Over the five fiscal years to 2025 free cash flow shrank at a compound 10.6% a year.

What are the highest and lowest free cash flow figures on record for Avantor?

Across the 9 fiscal years on record (2017–2025), the highest was $868.20M in fiscal 2020 and the lowest -$192.70M in fiscal 2017.

How is Avantor's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Avantor it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Avantor (AVTR) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/AVTR/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.